Clinical Trial Update: A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis [Phase 2]

View source ↗

Summary

Phase 2 study of TQ05105 tablets for moderate-to-high-risk myelofibrosis is currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis

Drugs mentioned

• TQ05105

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Moderate and High Risk Myelofibrosis | Phase 2 | Status: ACTIVE_NOT_RECRUITING